Investors generally liked Verastem’s rapid development of its FAK program, in particular the speed with which it’s advancing its lead candidate VS-6063 and expanding it across various tumor types. Several analysts covering the company bumped up its price target a few points.
At its first clinical-stage R&D day July 11, the company trumpeted its FAK (focal adhesion kinase) inhibitor program, including VS-6063, acquired from Pfizer Inc. in July 2012 and currently in ovarian cancer trials and soon to start in mesothelioma; and its follow-on FAK candidate VS-4718, licensed from Scripps Research Institute/Poniard Pharmaceuticals Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?